Scanned by

    Norton

    Norton™ Safe Web

    2023 OTS Paper of the Year by Jinkuk Kim: A Framework for Indiv. Splice-Switching Oligotherapy

    2023 OTS Paper of the Year by Jinkuk Kim: A Framework for Indiv. Splice-Switching Oligotherapy

    01:14:40 |
    Download Here

    You Might Also Like:

    Cytotoxicity of Modified Oligonucleotides: Sequence & Structure Impact | Dr. Croft & Dr. Fisher

    Cytotoxicity of Modified Oligonucleotides: Sequence & Structure Impact | Dr. Croft & Dr. Fisher

    1:00:57 |
    Shalini Andersson: Developing Oligonucleotides Into Therapies

    Shalini Andersson: Developing Oligonucleotides Into Therapies

    54:11 |
    2023 OTS Paper of the Year by Jinkuk Kim: A Framework for Indiv. Splice-Switching Oligotherapy

    2023 OTS Paper of the Year by Jinkuk Kim: A Framework for Indiv. Splice-Switching Oligotherapy

    1:14:41 |
    Antisense oligonucleotide therapy

    Antisense oligonucleotide therapy

    23:35 |
    Nucleic Acid Therapeutics: Successes, Milestones, and Upcoming Innovation

    Nucleic Acid Therapeutics: Successes, Milestones, and Upcoming Innovation

    1:02:45 |
    Chemistry of Therapeutic Oligonucleotides: A Brief Overview

    Chemistry of Therapeutic Oligonucleotides: A Brief Overview

    33:21 |
    Julia Alterman | Application of Hydrophobically Conjugated siRNAs for Skin & Muscle Disease

    Julia Alterman | Application of Hydrophobically Conjugated siRNAs for Skin & Muscle Disease

    1:04:14 |
    Oligonucleotide Therapeutics: New Drugs That Could Stop COVID-19

    Oligonucleotide Therapeutics: New Drugs That Could Stop COVID-19

    13:49 |
    RNA Targeting Technology – Chemistry and Delivery | Richard Geary

    RNA Targeting Technology – Chemistry and Delivery | Richard Geary

    1:10:26 |
    Chemistry of Oligonucleotide Therapeutics 101

    Chemistry of Oligonucleotide Therapeutics 101

    22:47 |
    Quantification Methods for oligonucleotide therapeutics in serum and tissue

    Quantification Methods for oligonucleotide therapeutics in serum and tissue

    35:00 |
    Chemical and Nanotechnology based Approaches to Build Next gen Oligonucleotide Therapeutics

    Chemical and Nanotechnology based Approaches to Build Next gen Oligonucleotide Therapeutics

    1:01:28 |
    John Chaput | A Nucleic Acid Approach to Antibody Therapeutics

    John Chaput | A Nucleic Acid Approach to Antibody Therapeutics

    1:02:27 |
    Antisense approaches for the treatment of Duchenne muscular dystrophy | Aurélie Goyenvalle

    Antisense approaches for the treatment of Duchenne muscular dystrophy | Aurélie Goyenvalle

    1:00:39 |
    Regulatory Applications of a Nonclinical Database for Oligonucleotide Therapeutics at U.S. FDA

    Regulatory Applications of a Nonclinical Database for Oligonucleotide Therapeutics at U.S. FDA

    25:14 |
    New Approach for Safety Evaluation of Oligonucleotide Therapeutics Using RNAseq

    New Approach for Safety Evaluation of Oligonucleotide Therapeutics Using RNAseq

    24:01 |
    Amy Byrnes: ASO activity and distribution after LNP delivery

    Amy Byrnes: ASO activity and distribution after LNP delivery

    1:02:51 |
    Applications of Oligonucleotides

    Applications of Oligonucleotides

    2:05 |
    Addressing Delivery Hurdles in the Translation of Oligonucleotide Therapeutics

    Addressing Delivery Hurdles in the Translation of Oligonucleotide Therapeutics

    31:01 |
    Oligo Meeting 2017 - Target Knock Down - ASOs and siRNA

    Oligo Meeting 2017 - Target Knock Down - ASOs and siRNA

    17:38 |